Content area

|
|

Hormonsubstitution efter salpingo-ooforektomi hos BRCA1/2-mutationsbærere øger ikke risikoen for brystkræft

Forfatter(e)
Astrid Sørbrøden Breda & Jan Blaakær Gynækologisk-obstetrisk Afdeling, Aarhus Universitetshospital Ugeskr Læger 2014;176:V03130186
Reference: 
Ugeskr Læger 2014;176:V03130186
Blad nummer: 
Sidetal: 
1772-1774
Hormone replacement therapy after salpingo-oophorectomy in BRCA 1/2 mutation carriers does not increase the risk of breast cancer
Prophylactic bilateral salpingo-oophorectomy (PBSO) reduces the risk of breast- and ovarian cancer in breast cancer gene (BRCA)1/2 mutation carriers. Women choose hormone replacement therapy (HT) to alleviate climacteric symptoms. Studies have shown a higher risk of breast cancer in healthy post-menopausal women getting HT. Further research among women with BRCA1/2 mutations is essential. No studies showed significantly that short-term use of HT alters the reduction in breast cancer risk associated with PBSO. Neither was there found any significant difference in type of HT chosen.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Kristian Østergaard | 27/09
4 kommentarer
af Julius Vindbjerg Nissen | 26/09
1 Kommentar
af Kamaran Shorsh | 24/09
2 kommentarer
af Julius Vindbjerg Nissen | 24/09
4 kommentarer
af Carsten Anker Edmund | 24/09
26 kommentarer
af Helle Lone Jensen | 23/09
1 Kommentar
af Martin Gottliebsen | 21/09
2 kommentarer
af Bente Ulla Rasmusson | 20/09
1 Kommentar